Synovial sarcoma is a rare, aggressive cancer with limited treatment options. Tecelra, the first T-cell receptor (TCR) gene therapy approved in the U.S., marks a major breakthrough by engineering patients’ T-cells to target tumor antigens. It has shown promising responses in advanced cases, offering new hope and advancing precision cancer therapy.

<h2>What Is Rhabdomyosarcoma?</h2><p><strong>Rhabdomyosarcoma (RMS)</strong> is the <strong>most common soft tissue sarcoma in children and adolescents</strong>, accounting for approximately <strong>3%–4% of all childhood cancers</strong> and approximately <strong>350 new cases per year</strong> in the United States. RMS arises from <strong>primitive mesenchymal cells</strong> that normally give rise to skeletal muscle, though it can occur in sites that lack skeletal muscle (

<h2>What Is Leiomyosarcoma?</h2><p><strong>Leiomyosarcoma (LMS)</strong> is the <strong>second most common soft tissue sarcoma</strong>, arising from <strong>smooth muscle cells</strong>. It can develop virtually anywhere in the body where smooth muscle is present — most commonly the <strong>uterus, retroperitoneum, and major blood vessel walls</strong>. LMS is broadly categorized into two major subtypes: <strong>uterine LMS (uLMS)</strong> and <strong>soft tissue / retroperi

<h2>What Is Liposarcoma?</h2><p><strong>Liposarcoma</strong> is the most common subtype of soft tissue sarcoma, arising from <strong>adipose (fat) tissue</strong>. It accounts for approximately <strong>20% of all soft tissue sarcomas</strong> and most frequently occurs in the <strong>retroperitoneum and extremities</strong>. Liposarcoma encompasses five major subtypes with markedly different biologies: <strong>well-differentiated liposarcoma (WDLPS)</strong> and <strong>dedif

<h2>What Is Osteosarcoma?</h2><p><strong>Osteosarcoma</strong> is the most common primary malignant bone tumor, accounting for approximately <strong>800–900 new cases annually</strong> in the United States. It primarily affects <strong>children, adolescents, and young adults</strong> (peak incidence in the second decade of life), with a second smaller peak in patients over 65. The tumor most frequently arises in the <strong>metaphysis of long bones</strong> — particularly the

</style><h2>What Is Malignant Mesothelioma?</h2><p>Malignant mesothelioma is a cancer arising from the mesothelial cells lining the pleura, peritoneum, pericardium, or tunica vaginalis testis. In the United States, its incidence is approximately 0.6–1.0 per 100,000, with about 2,500–3,000 new diagnoses annually, making it one of the more prevalent rare solid tumors. The primary cause is prior asbestos exposure, with a latency period of 20–50 years; most patients are therefore

</style><h2>What Is Squamous Cell Carcinoma of the Anal Canal?</h2><p>Squamous cell carcinoma of the anal canal (SCAC) is a malignancy arising from the epithelium of the anal canal. In the United States, its incidence is approximately 2.0 per 100,000, with about 10,000 new diagnoses annually — making it one of the more prevalent rare cancers. The primary cause is persistent infection with human papillomavirus (HPV, particularly HPV-16/18); high-risk groups include HIV-positiv

</style><h2>What Is Squamous Cell Carcinoma of the Anal Canal?</h2><p>Squamous cell carcinoma of the anal canal (SCAC) is a malignancy arising from the epithelium of the anal canal. In the United States, its incidence is approximately 2.0 per 100,000, with about 10,000 new diagnoses annually — making it one of the more prevalent rare cancers. The primary cause is persistent infection with human papillomavirus (HPV, particularly HPV-16/18); high-risk groups include HIV-positiv